Clinical trials: Non-Small Cell Lung
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
This is a single center, open-label, nonrandomized, phase 1b, dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
- Trial name
- NCT03780010
- Testing
- TRC105
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Lung Cancer
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00454194
- Testing
- pemetrexed disodium, sorafenib tosylate
- Where
- 207 sites in United States
- Volunteers
- 110 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Squamous Cell, Non-small-cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976362
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Survival Prolongation by Rationale Innovative Genomics
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if…
- Trial name
- SPRING (NCT03386929)
- Testing
- Avelumab, Axitinib, Palbociclib
- Where
- 5 sites in United States, Israel and 2 more
- Volunteers
- 15 people
- Sponsor
- Worldwide Innovative Network Association
Non-Small-Cell Lung Carcinoma
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with…
- Trial name
- NCT00112294
- Testing
- Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin
- Where
- 124 sites in United States
- Volunteers
- 755 people
- Sponsor
- Eli Lilly and Company
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer
This pilot phase II trial studies how well pioglitazone works in treating patients with stage IA-IIIA non-small cell lung cancer.
- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT01342770
- Testing
- Laboratory Biomarker Analysis, Pioglitazone Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Stage IV Non-small Cell Lung Cancer
BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
The treatment landscape of metastatic non small cell lung cancer (NSCLC) is rapidly evolving. There are new diagnostic and treatment options available in the coming months and years.
- Trial name
- BEPACT- Lung (NCT03959137)
- Testing
- None - Common practice
- Where
- 21 sites in Belgium
- Volunteers
- 215 people
- Sponsor
- MSD Belgium BVBA
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
Randomized phase III trial to determine the effectiveness of carboxyamidotriazole in treating patients who have stage III or stage IV non-small cell lung cancer.
- Conditions
- Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00003869
- Testing
- carboxyamidotriazole, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Non Small Cell Lung Cancer Metastatic
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma.
- Conditions
- Cancer, Non Small Cell Lung Cancer Metastatic, Metastatic Melanoma, Neoplasm of Lung
- Trial name
- NCT03123783
- Testing
- APX005M, Nivolumab
- Where
- 23 sites in United States, Spain
- Volunteers
- 140 people
- Sponsor
- Apexigen America, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
- Trial name
- NCT04025879
- Testing
- Nivolumab, Carboplatin, Cisplatin
- Where
- 108 sites in United States, Argentina and 20 more
- Volunteers
- 461 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Carcinoma
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT05110196
- Testing
- Capmatinib 150 mg, Capmatinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.
- Trial name
- NCT06790303
- Testing
- Feladilimab, Ipilimumab
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Non Small Cell Lung Carcinoma
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Background: AZD6244 (ARRY-142886) is an investigational anticancer drug that is designed to block a critical component (MEK (methyl ethyl ketone)) of a pathway (MAP (mitogen-activated protein) kinase pathway) that causes some…
- Trial name
- NCT01229150
- Testing
- AZD6244, Erlotinib, AZD6244 + Erlotinib
- Where
- 5 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or IIB (to T2) resectable Non-Small Cell Lung…
- Trial name
- NCT00367679
- Testing
- Pazopanib
- Where
- 12 sites in United States, Israel and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Muscle Wasting, Non-Small Cell Lung Cancer
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
- Trial name
- NCT01355497
- Testing
- GTx-024
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- GTx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.